btk
No description yet: the sentence for this tag has not been written. 4 records carry it: 4 people.
4 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Constantine S. Tam Head of Lymphoma Service, Alfred Health; Professor of Haematology, Monash University · Alfred Health / Monash University Led the zanubrutinib SEQUOIA trial and the first ibrutinib-venetoclax study in mantle cell lymphoma. | Chronic lymphocytic leukaemia, Mantle cell lymphoma | none | cll, australia | ||
Jennifer A. Woyach Professor of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center · The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute Led Alliance A041202, which showed ibrutinib beats chemoimmunotherapy in older CLL patients, and discovered BTK C481S resistance. | Chronic lymphocytic leukaemia | none | cll, alliance | ||
Jennifer R. Brown Director, CLL Center, Dana-Farber Cancer Institute; Worthington and Margaret Collette Professor of Medicine, Harvard Medical School · Dana-Farber Brigham Cancer Center Led ALPINE, the first head-to-head trial in which a next-generation BTK inhibitor (zanubrutinib) beat ibrutinib. | Chronic lymphocytic leukaemia | none | cll, trialist | ||
John C. Byrd Chair, Department of Internal Medicine, University of Cincinnati College of Medicine · University of Cincinnati Cancer Center Led the ibrutinib trials that turned CLL from a chemotherapy disease into one treated with pills. | Chronic lymphocytic leukaemia | none | cll, targeted-therapy |